ConductScience.org, home

Trial · NCT00752726

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChange From Baseline to Week 24 in Abdominal VAT MassBaseline to week 24VAT was measured by the computed tomography (CT) scan.
SecondaryChange From Baseline to Week 12 in Abdominal VAT MassBaseline to week 12Abdominal VAT mass from baseline to week 12 was measured by CT scan.
SecondaryChange From Baseline to Week 24 in Body WeightBaseline to week 24Participants were weighed at least twice until two consecutive measurements were within 0.5 kg of each other and the average of the two measurements was recorded.
SecondaryChange From Baseline to Week 24 in Total Fat MassBaseline to week 24Change in total fat mass was calculated from an average of three measurements at each visit from Echo Magnetic Resonance Imaging (EchoMRI).
SecondaryChange From Baseline to Week 24 in Percentage Body FatBaseline to week 24Body fat was assessed through Bioelectrical Impedance Analysis (BIA).
SecondaryChange From Baseline to Week 24 in Waist CircumferenceBaseline to week 24Waist circumference was measured against the skin, without interference from clothing, at the level midway between the lateral lower rib margin and the iliac crest in standing position.
SecondaryChange From Baseline to Week 24 in Percentage Liver FatBaseline to week 24For Liver fat, Intrahepatic lipids (IHL) were measured by Magnetic Resonance Spectroscopy (MRS).
SecondaryChange From Baseline to Week 24 in Liver FatBaseline to week 24The liver fat was measured by CT scan in Hounsfield Units (HU).
SecondaryChange From Baseline to Week 24 in Total Calories Expended for Physical ActivityBaseline to week 24Measurement of physical activity from Paffenbarger questionnaire. The number of caloried expended was representation of activity level: Higher calorie counts indicate higher activity
SecondaryChange From Baseline to Week 24 in Quality of Life (QoL) Scores.Baseline to week 24
QoL scores were measured using an Impact of Weight Quality of Life (IWQoL) Questionnaire, which scored the responses at a scale of 1 to 5(1, never true, to 5, always true): QoL scales for physical function, self-esteem, sexual life, public distress, and work were evaluated, and summarized in a total score. A higher value indicated a better quality of life.
SecondarySelectivity Index at Week 24Baseline to week 24
The selectivity index (SI) was used as a measure of orlistat's ability to target abdominal VAT loss compared to total adipose tissue lost. SI was calculated using the following equation: Mean % change in VAT divided by Mean % change in total fat mass.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00752726/registered